Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial closure: PR17

PR17: Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET

PR17 randomization ceased on March 24, 2017. The target accrual has been previously reached and a total of 1125 patients were randomized. CCTG led the non-ANZUP accrual with 22 sites activated and 204 patients randomized.

Status: Closed to Accrual
Activation Date: February 02, 2015

Men starting first-line androgen deprivation therapy for metastatic adenocarcinoma of the prostate. Key eligibility criteria include metastatic prostate cancer, adequate organ function and ECOG performance status 0-2.

Primary endpoint: Overall survival

If you have questions please contact the Study Coordinator, Alexander Montenegro